-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
New developments in the diagnosis and treatment of axial spondyloarthritis
Pedro Machado, Robert Landewe, Desiree van der Heijde
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the diagnosis and treatment of axial spondyloarthritis
Pedro Machado, Robert Landewe, Desiree van der Heijde
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the diagnosis and treatment of axial spondyloarthritis
Pedro Machado, Robert Landewe, Desiree van der Heijde
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the diagnosis and treatment of axial spondyloarthritis
Pedro Machado, Robert Landewe, Desiree van der Heijde
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the diagnosis and treatment of axial spondyloarthritis
Pedro Machado, Robert Landewe, Desiree van der Heijde
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the diagnosis and treatment of axial spondyloarthritis
Pedro Machado, Robert Landewe, Desiree van der Heijde
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the diagnosis and treatment of axial spondyloarthritis
Pedro Machado, Robert Landewe, Desiree van der Heijde
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the diagnosis and treatment of axial spondyloarthritis
Pedro Machado, Robert Landewe, Desiree van der Heijde
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation